Chromosomal copy number alterations for associations of ductal carcinoma in situ with invasive breast cancer.

PubWeight™: 0.84‹?›

🔗 View Article (PMC 4534146)

Published in Breast Cancer Res on August 13, 2015

Authors

Anosheh Afghahi1, Erna Forgó2, Aya A Mitani3, Manisha Desai4, Sushama Varma5, Tina Seto6, Joseph Rigdon7, Kristin C Jensen8,9, Megan L Troxell10, Scarlett Lin Gomez11,12, Amar K Das13,14, Andrew H Beck15, Allison W Kurian16,17, Robert B West18

Author Affiliations

1: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. anosheh@stanford.edu.
2: Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA. eforgo@stanford.edu.
3: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. amitani@bu.edu.
4: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. manishad@stanford.edu.
5: Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA. svarma@stanford.edu.
6: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. tseto@stanford.edu.
7: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. jrigdon@stanford.edu.
8: Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA. kjensen1@stanford.edu.
9: Pathology and Laboratory Medicine, Palo Alto Veterans Affairs Health Care System, 795 Willow Road, Palo Alto, CA, 94025, USA. kjensen1@stanford.edu.
10: Department of Pathology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA. troxellm@ohsu.edu.
11: Department of Health Research and Policy, Stanford University School of Medicine, 900 Blake Wilbur Drive, Stanford, CA, 94305, USA. Scarlett.Gomez@cpic.org.
12: Cancer Prevention Institute of California (CPIC), 2201 Walnut Avenue, Fremont, CA, 94538, USA. Scarlett.Gomez@cpic.org.
13: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. Amarendra.K.Das@dartmouth.edu.
14: Department of Psychiatry and The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, 1 Rope Ferry Road, Lebanon, NH, 03755, USA. Amarendra.K.Das@dartmouth.edu.
15: Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA. abeck2@bidmc.harvard.edu.
16: Department of Medicine, Stanford University School of Medicine, 291 Campus Drive, Stanford, CA, 94305, USA. akurian@stanford.edu.
17: Department of Health Research and Policy, Stanford University School of Medicine, 900 Blake Wilbur Drive, Stanford, CA, 94305, USA. akurian@stanford.edu.
18: Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, 94305, USA. rbwest@stanford.edu.

Articles citing this

The Predictive Link between Matrix and Metastasis. Curr Opin Chem Eng (2016) 0.75

Molecular biology: Marked progress. Nature (2015) 0.75

Articles cited by this

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72

Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med (1985) 7.22

Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28

Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet (2003) 6.15

Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol (2006) 4.87

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst (2010) 4.57

Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol (1998) 3.94

The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst (2011) 3.54

Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol (2001) 3.00

A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56

Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51

Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer (1989) 2.28

A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A (2006) 2.08

Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06

The molecular pathology of breast cancer progression. J Pathol (2010) 1.65

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res (2005) 1.64

Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res Treat (2009) 1.55

Genome evolution during progression to breast cancer. Genome Res (2013) 1.37

The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol (2002) 1.35

Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors. J Pathol (2006) 1.19

New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat (2008) 1.07

Breast cancer treatment across health care systems: linking electronic medical records and state registry data to enable outcomes research. Cancer (2013) 1.05

Oncoshare: lessons learned from building an integrated multi-institutional database for comparative effectiveness research. AMIA Annu Symp Proc (2012) 0.99

Effect of screening mammography on breast cancer incidence. N Engl J Med (2013) 0.96

Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. Mod Pathol (2013) 0.92

Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions. Mod Pathol (2012) 0.92

MAST2 and NOTCH1 translocations in breast carcinoma and associated pre-invasive lesions. Hum Pathol (2013) 0.82

DCIS and LCIS are confusing and outdated terms. They should be abandoned in favor of ductal intraepithelial neoplasia (DIN) and lobular intraepithelial neoplasia (LIN). Breast (2013) 0.80

Chromosomal alterations in pure nonneoplastic breast lesions: implications for breast cancer progression. Ann Surg Oncol (2010) 0.77